Spyre Therapeutics (SYRE) Receivables - Accured (2019 - 2026)
Spyre Therapeutics' (SYRE) quarterly Receivables - Accured came in at $4.6 million in Q1 2026, up 35.29% YoY from $3.4 million in Q1 2025, and up 2.22% on a QoQ basis from $4.5 million in Q4 2025.
Spyre Therapeutics (SYRE) Receivables - Accured (2019 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 8 years of Receivables - Accured data on file, last reported at $4.6 million in Q1 2026.
- Quarterly Receivables - Accured rose 35.29% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 35.29% YoY) and the FY2025 annual result came in at $4.5 million, up 32.35% from the prior year.
- Receivables - Accured rose to $4.6 million in Q1 2026, from $4.5 million in the prior quarter.
- In the past five years, Receivables - Accured ranged from a high of $4.6 million in Q1 2026 to a low of $100000.0 in Q4 2022.
- A 5-year average of $2.1 million and a median of $1.8 million in 2024 frame the typical range for Receivables - Accured.
- Annual changes were most pronounced in 2022 — Receivables - Accured changed 0.0% — and 2024, when it soared 1700.0%.
- Tracing SYRE's Receivables - Accured over 5 years: stood at $100000.0 in 2022, then surged by 800.0% to $900000.0 in 2023, then soared by 277.78% to $3.4 million in 2024, then surged by 32.35% to $4.5 million in 2025, then gained by 2.22% to $4.6 million in 2026.
- The last three Receivables - Accured figures came in at $4.6 million (Q1 2026), $4.5 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | 5.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.80 Mn |
| Jun 30, 2026 | 5.80 Mn |
| Mar 31, 2026 | 4.60 Mn |
| Mar 31, 2026 | 4.60 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 3.60 Mn |
| Sep 30, 2025 | 3.60 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 3.40 Mn |
| Mar 31, 2025 | 3.40 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.30 Mn |